Kidney

First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s Phase 1/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers

Retrieved on: 
Thursday, January 25, 2024

AU-007 is a human IgG1 monoclonal antibody designed to harness the power of interleukin-2 (IL-2) to eradicate solid tumors, and the first AI-designed human monoclonal antibody to be tested in a clinical trial.

Key Points: 
  • AU-007 is a human IgG1 monoclonal antibody designed to harness the power of interleukin-2 (IL-2) to eradicate solid tumors, and the first AI-designed human monoclonal antibody to be tested in a clinical trial.
  • Phase 1 data demonstrate that AU-007 is currently the only IL-2 agent that can reduce regulatory T cells (Tregs), which suppress the immune system.
  • This redirects IL-2 to medium-affinity receptors on effector T cells (Teffs) and natural killer (NK) cells, which expand and kill tumor cells.
  • To learn more about the AU-007 clinical trial program, please visit ClinicalTrials.gov (identifier: NCT05267626 ).

Monogram Health and Blue Cross Blue Shield of Arizona Partner to Improve Chronic Kidney Disease Outcomes

Retrieved on: 
Monday, January 29, 2024

NASHVILLE, Tenn. and PHOENIX, Jan. 29, 2024 /PRNewswire/ -- Blue Cross Blue Shield of Arizona (AZ Blue) today announced a partnership with Monogram Health, the nation's leading value-based provider of in-home, evidence-based care and benefit management services for patients living with chronic kidney and end stage kidney disease. Through this partnership, AZ Blue will use Monogram's extensive network of in-home providers and support services to improve the care of their members.

Key Points: 
  • Partnership in delivering high quality, affordable care to BCBSAZ Health Choice Pathway HMO D-SNP members managing polychronic kidney disease
    NASHVILLE, Tenn. and PHOENIX, Jan. 29, 2024 /PRNewswire/ -- Blue Cross Blue Shield of Arizona (AZ Blue) today announced a partnership with Monogram Health , the nation's leading value-based provider of in-home, evidence-based care and benefit management services for patients living with chronic kidney and end stage kidney disease.
  • Through this partnership, AZ Blue will use Monogram's extensive network of in-home providers and support services to improve the care of their members.
  • "We're proud to embark on this value-based care journey with Monogram Health to provide improved patient experiences, achieve better health outcomes and reduce variability in care," said Shawn Nau, General Manager, Medicaid Segment at Blue Cross Blue Shield of Arizona.
  • As part of this collaboration, Monogram Health will assume full financial risk for BCBSAZ's Health Choice Pathway D-SNP Product members with kidney disease.

AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma

Retrieved on: 
Monday, January 22, 2024

In MANDALA, AIRSUPRA was superior to albuterol in reducing the risk of severe asthma exacerbations in patients with moderate to severe asthma.

Key Points: 
  • In MANDALA, AIRSUPRA was superior to albuterol in reducing the risk of severe asthma exacerbations in patients with moderate to severe asthma.
  • In DENALI, AIRSUPRA had a similar onset of bronchodilation compared to albuterol in patients with mild to moderate asthma.2
    The approach to treating asthma symptoms with rescue has changed.
  • The 2023 Global Initiative for Asthma (GINA) report supports a rescue approach that treats both symptoms and inflammation together.
  • Now, with AIRSUPRA available we can provide patients, especially those on maintenance therapy, another rescue option for managing their breakthrough symptoms.

Injectable Angioplasty Balloon Catheter Transforms Peripheral Procedures, Users Report Reduced Equipment and Contrast Needs

Retrieved on: 
Wednesday, January 17, 2024

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    The Summa Finesse Injectable catheter is the industry’s first hybrid diagnostic and therapeutic angioplasty balloon catheter developed to facilitate treatment of patients at risk of limb loss due to below-knee PAD.
  • It was designed to improve the efficiency of peripheral angioplasty procedures by reducing equipment and contrast needs.
  • “In our busy limb salvage practice, it will be an important tool.”
    The Summa Finesse Injectable is a multifunctional catheter that serves as a crossing catheter, diagnostic angiography catheter, and angioplasty catheter to reduce equipment and contrast needs.
  • The Summa Finesse Injectable is the first hybrid catheter launched in the planned line of interventional radiology devices from Summa.

In the War on Cancer, Tampa General Hospital Cancer Institute Employs AI in its Newly Established Center for Precision Radiosurgery

Retrieved on: 
Thursday, January 25, 2024

TAMPA, Fla., Jan. 25, 2024 /PRNewswire/ -- Going under the knife is taking on a new and more promising meaning at Tampa General Hospital (TGH) Cancer Institute, where doctors are using a sophisticated AI-driven tool to treat cancer.

Key Points: 
  • TAMPA, Fla., Jan. 25, 2024 /PRNewswire/ -- Going under the knife is taking on a new and more promising meaning at Tampa General Hospital (TGH) Cancer Institute , where doctors are using a sophisticated AI-driven tool to treat cancer.
  • It is capable of treating cancerous and benign tumors throughout the body, as well as neurologic disorders, in as little as 15 minutes.
  • The tool, through its speed and advanced precision, is expected to expand the capabilities of Tampa General Cancer Institute's newly established Center for Precision Radiosurgery, said Dr. Richard Tuli, professor and chair of the Department of Radiation Oncology at USF Health Morsani College of Medicine, deputy director of the TGH Cancer Institute, and director of Radiation Oncology at Tampa General.
  • Tuli joined TGH from Memorial Sloan Kettering Cancer Center in New York, N.Y.
    "It's another example of providing our patients with the best possible care across the Tampa Bay region and the state,'' he said.

Supportive, Stable Caregiving in Childhood Protects Heart Health in Adulthood

Retrieved on: 
Tuesday, January 23, 2024

New research, however, shows that receiving warmth from a caregiver during childhood protects cardiovascular health later in life, according to a study led by NYU Grossman School of Medicine and The Ohio State University Wexler Medical Center.

Key Points: 
  • New research, however, shows that receiving warmth from a caregiver during childhood protects cardiovascular health later in life, according to a study led by NYU Grossman School of Medicine and The Ohio State University Wexler Medical Center.
  • "At the same time, our findings show that adversity in early childhood does not equal destiny.
  • While adverse childhood family environments were associated with lower odds of cardiovascular health in adulthood, our findings suggest that supportive and, importantly, stable caregiving may have a stronger influence on later heart health than early adversity."
  • The hope, says Ortiz, is that this study offers insight into how supporting healthy, both supportive and stable, caregiving relationships in childhood can offer greater attainment of CVH at a population level.

Global Urinary Tract Infection (UTI) Treatment Market is expected to Reach US$ 13,617.4 million by 2034, rising at a 1.9% CAGR- FMI Study

Retrieved on: 
Monday, January 22, 2024

NEWARK, Del., Jan. 22, 2024 /PRNewswire/ -- The Urinary Tract Infection (UTI) Treatment Market is estimated to be worth US$   11,244.0 million in 2024 and is projected to be valued at US$ 13,617.4 million in 2034. Between 2024 and 2034, the industry is expected to register a growth rate of 1.9%.

Key Points: 
  • Future Market Insights, Inc. (FMI) predicts a robust expansion of the urinary tract infection (UTI) treatment market, propelled by increasing infection rates, catheter use, and advancements in diagnosis and care.
  • Dive deeper into the intricate dynamics of this burgeoning market and uncover compelling stakeholder opportunities in our comprehensive FMI report.
  • NEWARK, Del., Jan. 22, 2024 /PRNewswire/ -- The Urinary Tract Infection (UTI) Treatment Market is estimated to be worth US$   11,244.0 million in 2024 and is projected to be valued at US$ 13,617.4 million in 2034.
  • Individuals using urinary catheters face an elevated risk of developing complicated urinary tract infections, driving the demand for UTI treatment .

MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials.

Retrieved on: 
Wednesday, January 17, 2024

MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials.

Key Points: 
  • MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials.
  • Applications to the FDA for global phase III clinical trials are expected to take place in the second quarter of 2024.
  • Megapro states that the diagnosis of focal liver lesion by contrast-enhanced MRI remained an important clinical needs globally.
  • Therefore, MegaPro plans to further develop the MPB1523, nano-iron oxide MRI contrast agent, for its phase 3 study.

AM-Pharma Initiates Phase 2 Trial of Ilofotase Alfa for Cardiac Surgery-Associated Renal Damage

Retrieved on: 
Tuesday, January 16, 2024

CSA-RD is defined as the long-term loss of renal function in cardiac surgery patients and arises from acute kidney injury (AKI) immediately following the surgery.

Key Points: 
  • CSA-RD is defined as the long-term loss of renal function in cardiac surgery patients and arises from acute kidney injury (AKI) immediately following the surgery.
  • Ilofotase alfa has a proven safety and tolerability profile and a strong record of renal protective effects as observed in previous clinical studies.
  • Notably, prior Phase 2 and Phase 3 trials with ilofotase alfa demonstrated significant improvements in Major Adverse Kidney Events by day 90 (MAKE90) in sepsis-associated AKI.
  • Ilofotase alfa was recently evaluated in a Phase 1b pilot study as enzyme replacement therapy in hypophosphatasia (HPP) patients.

CORE Kidney's “Gift of Life: A Tune That Never Fades” Float Wins the Hearts of Rose Parade® Crowd, Recognized With 2024 Isabella Coleman Award

Retrieved on: 
Tuesday, January 16, 2024

A special thanks to Lyn Lofthouse for the floral decorations that won us the Isabella Coleman Award.

Key Points: 
  • A special thanks to Lyn Lofthouse for the floral decorations that won us the Isabella Coleman Award.
  • We are also very grateful to Steve Perry and the Tournament of Roses team for supporting us all along.
  • The float with the kidney-shaped tree sat living kidney donors, kidney health champions, in a beautiful colorful garden as they danced to, “Dancing in the Streets” tune!
  • CORE Kidney’s Rose Parade float was sponsored by Amgen, Baxter International, DaVita and Travere Therapeutics, who made it possible to feature living kidney donors on the float.